Design and Synthesis of Inhaled p38 Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease
- 28 October 2011
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 54 (22), 7797-7814
- https://doi.org/10.1021/jm200677b
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Selective p38α Inhibitors Clinically Evaluated for the Treatment of Chronic Inflammatory DisordersJournal of Medicinal Chemistry, 2009
- Glucocorticoid resistance in inflammatory diseasesThe Lancet, 2009
- Increased activation of p38 MAPK in COPDEuropean Respiratory Journal, 2008
- p38α-Selective Mitogen-Activated Protein Kinase Inhibitor SD-282 Reduces Inflammation in a Subchronic Model of Tobacco Smoke-Induced Airway InflammationThe Journal of pharmacology and experimental therapeutics, 2007
- Global burden of COPD: risk factors, prevalence, and future trendsThe Lancet, 2007
- Oral p38 Mitogen-Activated Protein Kinase Inhibition With BIRB 796 for Active Crohn’s Disease: A Randomized, Double-Blind, Placebo-Controlled TrialClinical Gastroenterology and Hepatology, 2006
- Inhaled p38α Mitogen-activated Protein Kinase Antisense Oligonucleotide Attenuates Asthma in MiceAmerican Journal of Respiratory and Critical Care Medicine, 2005
- Pharmacological treatment of established rheumatoid arthritisBest Practice & Research Clinical Rheumatology, 2003
- Food manufacturing and the allergic consumer: Accidents waiting to happenJournal of Allergy and Clinical Immunology, 2002
- Inflammatory cytokines: interleukin-1 and tumor necrosis factor as effector molecules in autoimmune diseasesCurrent Opinion in Immunology, 1991